Table 1 Previous reports of ATL development after allo-HSCT and organ transplantation and present our cases
References | Year | ATL | Development of ATL | Age, sex | Transplantation | Recipient HTLV-1 | Donor HTLV-1 | Immune suppression | Therapy for ATL | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|
HTLV-1-positive recipient or/and donor cohort after organ transplantation | ||||||||||
Kawano et al. [3] | 2006 (8 HTLV-1-positive liver transplantation cohort) | ATL | 6 months | 39, F | Liver trp | + | + | FK/PSL | Discontinuation of immune suppression agents | 15 days dead |
Yoshizumi et al. [15] | 2016 (82 HTLV-1-positive liver transplantation cohort in Japan) | |||||||||
Kawano et al. [3] | 2006 | ATL | 2 years | 45, M | Liver trp | + | + | FK/PSL | Chemotherapy LSG 15 ③ | 3 months dead |
Yoshizumi et al. [15] | 2016 | |||||||||
Kawano et al. [3] | 2006 | ATL | 9 months | 67, M | Liver trp | + | + | FK/PSL | Chemotherapy CHOP ① and CHOV-VMMV ③ | 5 months Dead |
Yoshizumi et al. [15] | 2016 | |||||||||
Yoshizumi et al. [15] | 2016 | ATL | 4 years | 48, M | Liver trp | – | + | CSP/PSL | Chemotherapy | 15 months dead |
Yoshizumi et al. [15] | 2016 | ATL | 1 year | 59, F | Liver trp | + | – | FK | n.d | 12 months dead |
Yamauchi and Yamano et al. [7] | 2019 (99 HTLV-1-positive renal transplantation cohort in Japan) | ATL | 10.2 years | n.d | Renal trp | + | – | n.d | n.d | Dead |
Present case | 2022 (4 HTLV-1-positive renal transplantation cohort) | ATL | 2 years and 9 months | 60, male | Renal trp | + | – | FK | CHOP therapy CBSCT | Dead (Mucor infection) (101 days) |
Present case | 2022 | ATL | 3 years and 3 months | 75, female | Renal trp | + | – | FK | PSL | Dead (5 days) |
Case report | ||||||||||
Glowacka et al. [20] | 2013 | ATL | 2 years | 59, M | Liver trp | – | + | FK/PSL | Chemotherapy | 27 months dead |
Zanke et al. [8] | 1989 | ATL | 2 years | 43, M | Renal trp | n.d | n.d | CSP/PSL | Chemotherapy CVP④ | 20 months alive |
Tsurumi et al. [9] | 1992 | ATL | 4 years | 32, M | Renal trp | + | – | CSP/mizoribine | Chemotherapy CHOP⑥, KM2210 | 13 months alive |
Williams et al. [11] | 1994 | ATL | 13 years | 42, M | Renal trp | n.d | n.d | Azathioprine/PSL | No treatment | 1 day dead |
Jenks et al. [10] | 1995 | ATL | 9 months | 61, M | Renal trp | + | – | CSP/azathioprine/PSL | Chemotherapy CHOP① | 5 days dead |
Mori et al. [12] | 2000 | ATL | 3 years | 49, F | Renal trp | n.d | n.d | FK/azathioprine/PSL | Chemotherapy CHOP① | 1 month dead |
Ichikawa et al. [14] | 2000 | ATL | 10 years | 42, M | Renal trp | – | n.d | CSP/azathioprine/PSL | Chemotherapy CHOP + radiation | 3 months dead |
Glowacka et al. [20] | 2013 | ATL | 2 years | 59, M | Liver trp | – | + | FK | PSL | alive |
Glowacka et al. [20] | 2013 | ATL | 3 years | 28, M | Renal trp | – | n.d | FK/MMF | PSL | alive |
Tamaki et al. [17] | 2006 | ATL | 2 months | 63, F | BMT | + | + | CSP/PSL | Irradiation of 3060 cGy and rapid reduction of immunosuppressive agents | 32 months live |
Nakamizo et al. [28] | 2011 | ATL | 6 years | 46, F | BMT | + | + | CSP | Whole brain irradiation and localized irradiation | 27 months alive |
Kitamura et al. [19] | 2017 | ATL | 16 months | 52, M | BMT | + | – | FK/PSL | PSL | Several months, PD |